Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients

Cancer

Volumn 104, Issue 12, 2005, Pages 2735-2742

  Ruiz Soto, Rodrigo ^a   Sergent, Guillaume ^b   Gisselbrecht, Christian ^b   Larghero, Jerome ^b   Ertault, Marjan ^b   Hennequin, Christophe ^b   Manson, Julien ^c   De Kerviler, Eric ^b   Briere, Josette ^b   Mounier, Nicolas ^b,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

Adult lymphoma; Agents Adverse effects; Antineoplastic; Autologous; Neoplasms; Non Hodgkin; Prognosis; Regression analysis; Second primary; Transplantation

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOXANTRONE; PREDNISONE; VINCRISTINE; VINDESINE; CD34 ANTIGEN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CARDIOTOXICITY; FEMALE; HUMAN; INFECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; WHOLE BODY RADIATION; AGGRESSIVE NONHODGKIN LYMPHOMA; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CATARACT; COMBINATION CHEMOTHERAPY; COMPETING RISK; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOCRINE DISEASE; FATIGUE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATOLOGIC MALIGNANCY; IATROGENIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LARGE CELL LYMPHOMA; LATE ADVERSE EVENT; LUNG DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OVERALL SURVIVAL; RISK; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; UROGENITAL TRACT DISEASE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 29144481913     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21492     Document Type: Article

References (31)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [see Comments]. N Engl J Med. 1993;329:987-994.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
3. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279-4284.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
5. Milpied JN, Deconinck E, Colombat P, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-1295.
6. Mounier N, Gisselbrecht C, Briere J, et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2004;22:2826-2834.
7. Haddy TB, Adde MA, McCalla J, et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol. 1998;16:2070-2079.
8. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527-2534.
9. Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:2535-2542.
10. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood. 1994;84:957-963.
11. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol. 1999;106:1020-1026.
12. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3128-3135.
13. Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18:947-955.
14. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588-1593.
15. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633-3639.
16. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906.
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
18. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
19. World Health Organization. Manual of the international statistical classification of disease, injuries and causes of death: based on the recommendations of the Ninth Revision Conference, 1975, and adopted by the Twenty-ninth World Health Assembly, vol. I. Geneva: World Health Organization, 1977.
20. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer, 2000.
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
22. Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant. 1990;5:173-177.
23. Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant. 2000;25:885-894.
24. van Besien K, Tabocoff J, Rodriguez M, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant. 1995;15:549-555.
25. Epelbaum R. Non-Hodgkin's lymphoma: long-term survivors and adverse effects. Ann Oncol. 2000;11(Suppl 3):123-128.
26. Pavlovsky S, Juni M, Milone G, Martinez-Rolon J, Fernandez I, Corrado C. Ten years of autologous peripheral stem cell transplantation with the same conditioning regimen (CBV) in 279 consecutive lymphoma patients done in a single center. Evaluation of prognostic factors affecting outcome. Proc Am Soc Clin Oncol. 2003;22:607 (Abstract 2441).
27. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Inwards DJ. High dose therapy with autologous stem cell transplantation (ASCT) for non-Hodgkin's lymphoma (NHL) in elderly patients. A single institution retrospective study. Blood. 2003;102 (Abstr 2719).
28. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:2208-2214.
29. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103:1222-1228.
30. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015-2023.
31. Park S, Brice P, Noguerra ME, et al. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2000;26:321-326.